Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus (Nasdaq: CERS) reported Q1 2026 total revenue $59.9M (up 23% YoY) and product revenue $53.7M (up 24% YoY). The company raised full‑year product revenue guidance to $227M–$231M, including IFC revenue $22M–$24M. Cash and short‑term investments were $80.4M at March 31, 2026. Net loss narrowed to $1.6M ($0.01 per share) and adjusted EBITDA was $4.0M. Management transition: COO Vivek Jayaraman named CEO effective July 1, 2026; current CEO becomes executive chairman.
Cerus (Nasdaq: CERS) signed a new four-year supply agreement with Établissement Français du Sang (EFS) for the INTERCEPT Blood System covering platelets, plasma and the next-generation INT200 LED illumination device.
The agreement continues EFS's nationwide use of INTERCEPT (platelets since 2006; nationwide rollout 2017) and supports distribution to ~330,000 platelet units annually across 13 regional centers and overseas territories.
Cerus Corporation (Nasdaq: CERS) will release first quarter 2026 financial results on April 30, 2026 after market close and will host a conference call and webcast at 4:30 P.M. ET that day.
According to the company, management will discuss financial results, provide a general business overview and outlook, and presentation slides and a replay will be available on the Cerus Investor Relations website through May 21, 2026.
Cerus (Nasdaq: CERS) named Vivek Jayaraman president and chief executive officer, effective July 1, 2026, with William “Obi” Greenman moving to executive chairman.
Mr. Jayaraman, Cerus COO since 2020, grew product revenue from under $40M to over $200M in 2025; Cerus has product sales in 40+ countries and four FDA approvals in the past decade.
Cerus (Nasdaq: CERS) reported 2025 total revenue of $233.8 million (+16% YoY) and product revenue of $206.1 million (+14% YoY).
Key items: IFC revenue rose ~80% to $16.7 million, GAAP net loss narrowed to $15.6 million, non-GAAP adjusted EBITDA was $9.5 million, cash and short-term investments were $82.9 million, and 2026 product revenue guidance is $224–228 million.
Cerus Corporation (Nasdaq: CERS) said company management will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 10:30 a.m. ET. A live webcast will be available on the company Investor Relations site, with a replay accessible for 90 days.
Cerus Corporation (Nasdaq: CERS) will release fourth quarter and full-year 2025 financial results on March 2, 2026 after market close.
The company will host a conference call and webcast at 4:30 P.M. ET to discuss results, outlook, and provide presentation slides; a replay will be available through March 23, 2026.
Cerus (Nasdaq: CERS) announced the start of the INITIATE study, a prospective, multicenter, non-interventional Post-Authorization Safety Study (PASS) led by the German Red Cross Blood Donation Service Baden-Württemberg–Hessen and its North-East subsidiary.
The study is the first in Germany to evaluate routine clinical use and the safety profile of platelet concentrates treated with Cerus’ INTERCEPT Blood System, and aims to assess operational integration, routine suitability, and feasibility of broader system-wide introduction of pathogen-inactivated platelets in German hospitals.
Cerus (Nasdaq: CERS) reported preliminary unaudited product revenue of $57.8M for Q4 2025 and $206.1M for full-year 2025, each up 14% versus 2024. INTERCEPT Fibrinogen Complex (IFC) contributed $4.2M in Q4 and $16.7M for the year, increases of ~40% and ~80% year-over-year, respectively. The company expects full-year 2026 product revenue of $224M–$228M (growth of 9%–11%) and forecasts 2026 IFC revenue of $20M–$22M (≈20%–30% growth). Key 2026 milestones include an FDA PMA submission for INT200 in mid-2026 and Phase 3 RedeS RBC trial results in H2 2026. Complete audited results and a business review will be presented on a hosted call in early March 2026.
Cerus Corporation (Nasdaq: CERS) announced a group purchasing agreement with Blood Centers of America (BCA) on December 10, 2025 covering Cerus’ entire INTERCEPT product line.
The agreement covers pathogen reduction for platelets, plasma and INTERCEPT Fibrinogen Complex (IFC), and will use a resource-sharing model to move ongoing IFC production across BCA member blood centers. BCA represents 60+ independent community blood centers that produce about half of U.S. platelet and cryoprecipitate supply. Cerus and BCA plan collaborative training and distribution to expand access and adoption of pathogen reduction technology.